论文部分内容阅读
目的:探讨丁苯酞联合阿托伐他汀钙治疗老年人急性脑梗死的疗效及对患者神经功能、氧化应激反应的影响。方法:选择湖州市第一人民医院2019年1-12月收治的老年急性脑梗死患者120例（有溶栓、取栓治疗禁忌证者），按照随机数字表法分为联合组和对照组各60例。在常规治疗（非溶栓、取栓疗法）的基础上，对照组采用阿托伐他汀钙治疗，联合组给予阿托伐他汀钙联合丁苯酞软胶囊治疗。两组疗程均为2周。比较两组治疗疗效，治疗前、治疗后1周和治疗后2周神经功能缺损程度（NIHSS）评分和Barthel指数评定量表（BI）评分及治疗前和治疗后2周氧化应激指标［丙二醛（MDA）、谷胱甘肽超氧化物酶（GSH-Px）和超氧化物歧化酶（SOD）］的变化。结果:联合组总有效率（93.33%）高于对照组（70.00%）（χn 2＝10.909，n P<0.05）；联合组治疗后1周、治疗后2周NIHSS评分分别为（7.83±0.67）分、（5.32±0.51）分，均低于对照组的（9.71±0.82）分、（7.18±0.63）分（n t=13.752、17.775，均n P<0.05）；联合组治疗后1周、治疗后2周BI评分分别为（54.37±3.18）分、（70.29±5.45）分，均高于对照组的（46.73±3.89）分、（59.83±6.38）分（n t=8.329、9.656，均n P<0.05）；联合组治疗后2周血清MDA（4.27±0.85）nmol/L，低于对照组的（6.73±1.20）nmol/L，而GSH-Px［（89.94±5.36）U/L］和SOD［（263.13±16.52）IU/L］，高于对照组的（76.83±4.61）U/L和（189.91±10.36）IU/L，两组差异均有统计学意义（n t=12.958、14.364、29.086，均n P<0.05）。n 结论:丁苯酞联合阿托伐他汀钙治疗老年人急性脑梗死疗效良好，可改善患者神经功能，及减轻氧化应激损伤。“,”Objective:To investigate the effect of butylphthalide combined with atorvastatin calcium in the treatment of elderly patients with acute cerebral infarction and its influence on neurological function and oxidative stress reaction.Methods:A total of 120 older adult patients with acute cerebral infarction (with contraindications of thrombolysis and thrombectomy) who received treatment in the First People's Hospital of Huzhou during January to December 2019 were included in this study. They were randomly assigned to receive treatment with atorvastatin calcium (control group, n n = 60) or butylphthalide combined with atorvastatin calcium (combined treatment group, n n = 60) for 2 weeks based on conventional non-thrombolysis and non-thrombectomy treatment. The therapeutic effect was compared between the control and the combined treatment groups. The National Institutes of Health Stroke Scale score and the Barthel Index before and 1 and 2 weeks after treatment, and serum levels of oxidative stress markers malondialdehyde (MDA), glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) before and 2 weeks after treatment were measured.n Results:Total effective rate in the combined treatment group was significantly higher than that in the control group (93.33%n vs. 70.00%, χn 2 = 10.909, n P < 0.05). At 1 and 2 weeks after treatment, the National Institutes of Health Stroke Scale score in the combined treatment group was (7.83 ± 0.67) points and (5.32 ± 0.51) points, respectively, which was significantly lower than (9.71 ± 0.82) points and (7.18 ± 0.63) points, respectively in the control group ( n t = 13.752, 17.775, both n P < 0.05). At 1 and 2 weeks after treatment, the Barthel Index in the combined treatment group was 54.37 ± 3.18 and 70.29 ± 5.45 respectively, which was significantly higher than 46.73 ± 3.89 and 59.83 ± 6.38, respectively in the control group ( n t = 8.329, 9.656, both n P < 0.05). At 2 weeks after treatment, serum level of malondialdehyde in the combined treatment group was significantly lower than that in the control group [(4.27 ± 0.85) nmol/L n vs. (6.73 ± 1.20) nmol/L. Serum levels of glutathione peroxidase [(89.94 ± 5.36) U/L] and superoxide dismutase [(263.13 ± 16.52) IU/L] in the combined treatment group were significantly higher than (76.83 ± 4.6) IU/L and (189.91 ± 10.36) IU/L in the control group, respectively (n t = 12.958, 14.364, 29.086, all n P < 0.05).n Conclusion:Butylphthalide combined with atorvastatin calcium in the treatment of older adult patients with acute cerebral infarction exhibits better therapeutic effect than atorvastatin calcium alone. It can improve neurological function and reduce oxidative stress injury.